血浆 microRNA-21 浓度可能是胶质母细胞瘤患者有用的生物标志物。
Plasma MicroRNA-21 concentration may be a useful biomarker in glioblastoma patients.
机构信息
Department of Medicine, Comprehensive Cancer Center-Central Nervous System Tumours Unit (CCC-CNS), Medical University of Vienna, Vienna, Austria.
出版信息
Cancer Invest. 2012 Oct;30(8):615-21. doi: 10.3109/07357907.2012.708071. Epub 2012 Aug 14.
BACKGROUND
MicroRNAs are proposed as plasma biomarkers in cancer. Glioblastoma is the most frequent primary brain tumor of adults. MicroRNA-21 was shown to induce glioblastoma growth.
AIMS
To evaluate the circulating microRNA-21 in glioblastoma patients.
METHODS
MicroRNA-21 copies in glioblastoma plasma (n = 10, before surgery and during/after concomitant chemoradiotherapy), control plasma (n = 10), and tissue samples were analyzed using RT-qPCR.
RESULTS
MicroRNA-21 in glioblastoma was significantly higher than controls (p = .02) and decreased significantly in 9 patients (p = .05). One patient with increasing microRNA-21 developed a histopathologically proven recurrence after the second sample collection.
DISCUSSION
Circulating microRNA-21 might be a useful biomarker in glioblastoma.
背景
microRNAs 被认为是癌症的血浆生物标志物。 胶质母细胞瘤是成人中最常见的原发性脑肿瘤。 microRNA-21 被证明可诱导胶质母细胞瘤生长。
目的
评估胶质母细胞瘤患者的循环 microRNA-21。
方法
使用 RT-qPCR 分析胶质母细胞瘤血浆（n = 10，手术前和同期放化疗期间/后）、对照血浆（n = 10）和组织样本中的 microRNA-21 拷贝数。
结果
胶质母细胞瘤中的 microRNA-21 明显高于对照组（p =.02），9 例患者明显降低（p =.05）。 第二个样本采集后，一名 microRNA-21 增加的患者出现了组织病理学证实的复发。
讨论
循环 microRNA-21 可能是胶质母细胞瘤的有用生物标志物。
Zotero 插件